osimertinib   Click here for help

GtoPdb Ligand ID: 7719

Synonyms: AZD 9291 | AZD-9291 | AZD9291 | mereletinib (obsolete INN) | Tagrisso®
Approved drug PDB Ligand
osimertinib is an approved drug (FDA (2015), EMA (2016))
Compound class: Synthetic organic
Comment: Osimertinib (AZD9291) is a third-generation, potent, selective and irreversible inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase bearing mutations which either sensitise the receptor, or cause drug resistance (eg the T790M mutation) [2]. The compound is less effective against the wild-type receptor.
This compound is included in AstaZeneca's Open Innovation Pharmacology Toolbox. There are reports of acquired resistance to osimertinib with tumours developing the C797S [6,9] and L718Q mutations [1] .

Third-generation mutant EGFR inhibitors are being developed to circumvent dose-limiting WT EGFR-driven toxicities such as gastrointestinal toxicity and rash. The progress being made in developing advanced generation EGFR inhibitors is discussed by Yu and Riely (2013) [8] and Ou and Soo (2015) [4].
Click here for help
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: osimertinib

2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 11
Topological polar surface area 87.55
Molecular weight 499.27
XLogP 3.6
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C=CC(=O)Nc1cc(Nc2nccc(n2)c2cn(c3c2cccc3)C)c(cc1N(CCN(C)C)C)OC
Isomeric SMILES C=CC(=O)Nc1cc(Nc2nccc(n2)c2cn(c3c2cccc3)C)c(cc1N(CCN(C)C)C)OC
InChI InChI=1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32)
InChI Key DUYJMQONPNNFPI-UHFFFAOYSA-N
Bioactivity Comments
Whilst AZD9291 has high in vitro affinity for mutant EGFRs, affinity for the wild type receptor is much lower (~ 490nM) [7]. In vitro IC50s for mutant EGFRs are reported as 1-15nM for the double L858R/T790M mutant, 17nM for the exon 19 deletion sensitising mutant, and 6nM for the dual exon 19 deletion/T790M mutant [2].
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
epidermal growth factor receptor Hs Inhibitor Inhibition 6.3 pIC50 - 7
pIC50 6.3 (IC50 4.94x10-7 M) [7]